Tags

Type your tag names separated by a space and hit enter

Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1031s-1036s.CC

Abstract

Results from multiple clinical trials involving aromatase inhibitors have added to the knowledge base relating to endocrine therapy of postmenopausal women with hormone receptor-positive early breast cancer. In the extended adjuvant setting, data from the Austrian Breast and Colorectal Cancer Study Group 6a trial showed an advantage for anastrozole following 5 years of tamoxifen treatment, consistent with the more robust MA.17 trial that examined letrozole versus placebo following 5 years of tamoxifen treatment. The combined analysis of the Austrian Breast and Colorectal Cancer Study Group 8 trial and the German Arimidex Nolvadex 95 trial, plus the Italian Tamoxifen Anastrozole trial, have shown the advantage of switching to anastrozole over continuing the tamoxifen to complete the full 5 years of adjuvant therapy. These trials support the previously reported larger and double-blind Intergroup Exemestane Study. The Arimidex, Tamoxifen, Alone or in Combination trial now has data out to 68 months of median follow-up showing the maintenance of a significant advantage of anastrozole over tamoxifen for disease-free survival. In this initial treatment setting, the Breast International Group 1-98 trial recently showed a significant advantage for letrozole over tamoxifen. The current debate is centered on whether the optimal strategy is to give an aromatase inhibitor initially or after several years of tamoxifen treatment. Multiple important questions remain, including the predictive value of molecular markers such as progesterone receptor, the optimal duration of aromatase inhibitor therapy, the long-term adverse effects, and the relative efficacy and toxicity of the different aromatase inhibitors.

Authors+Show Affiliations

Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MH 55905, USA. ingle.james@mayo.edu

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

16467121

Citation

Ingle, James N.. "Adjuvant Endocrine Therapy for Postmenopausal Women With Early Breast Cancer." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 12, no. 3 Pt 2, 2006, 1031s-1036s.
Ingle JN. Adjuvant endocrine therapy for postmenopausal women with early breast cancer. Clin Cancer Res. 2006;12(3 Pt 2):1031s-1036s.
Ingle, J. N. (2006). Adjuvant endocrine therapy for postmenopausal women with early breast cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 12(3 Pt 2), 1031s-1036s.
Ingle JN. Adjuvant Endocrine Therapy for Postmenopausal Women With Early Breast Cancer. Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1031s-1036s. PubMed PMID: 16467121.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Adjuvant endocrine therapy for postmenopausal women with early breast cancer. A1 - Ingle,James N, PY - 2006/2/10/pubmed PY - 2006/3/18/medline PY - 2006/2/10/entrez SP - 1031s EP - 1036s JF - Clinical cancer research : an official journal of the American Association for Cancer Research JO - Clin Cancer Res VL - 12 IS - 3 Pt 2 N2 - Results from multiple clinical trials involving aromatase inhibitors have added to the knowledge base relating to endocrine therapy of postmenopausal women with hormone receptor-positive early breast cancer. In the extended adjuvant setting, data from the Austrian Breast and Colorectal Cancer Study Group 6a trial showed an advantage for anastrozole following 5 years of tamoxifen treatment, consistent with the more robust MA.17 trial that examined letrozole versus placebo following 5 years of tamoxifen treatment. The combined analysis of the Austrian Breast and Colorectal Cancer Study Group 8 trial and the German Arimidex Nolvadex 95 trial, plus the Italian Tamoxifen Anastrozole trial, have shown the advantage of switching to anastrozole over continuing the tamoxifen to complete the full 5 years of adjuvant therapy. These trials support the previously reported larger and double-blind Intergroup Exemestane Study. The Arimidex, Tamoxifen, Alone or in Combination trial now has data out to 68 months of median follow-up showing the maintenance of a significant advantage of anastrozole over tamoxifen for disease-free survival. In this initial treatment setting, the Breast International Group 1-98 trial recently showed a significant advantage for letrozole over tamoxifen. The current debate is centered on whether the optimal strategy is to give an aromatase inhibitor initially or after several years of tamoxifen treatment. Multiple important questions remain, including the predictive value of molecular markers such as progesterone receptor, the optimal duration of aromatase inhibitor therapy, the long-term adverse effects, and the relative efficacy and toxicity of the different aromatase inhibitors. SN - 1078-0432 UR - https://www.unboundmedicine.com/medline/citation/16467121/Adjuvant_endocrine_therapy_for_postmenopausal_women_with_early_breast_cancer_ L2 - http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=16467121 DB - PRIME DP - Unbound Medicine ER -